男捅女洞口啪啪啪免费视频在线-老司机高清熟女一区-高潮的少妇中文字幕无码-黄片在线免费观看视频不卡-91久久久精品国产一区二区三区-成年美女视频在线观看-丝袜美女诱惑在线观看视频-免费播放婬乱男女婬视频国产-亚洲国产中文字幕免费

產品資料

Erlotinib, Hydrochloride Salt **

如果您對該產品感興趣的話,可以
產品名稱: Erlotinib, Hydrochloride Salt **
產品型號: LC E-4007
產品展商: 原裝進口
產品文檔: 無相關文檔

簡單介紹

Erlotinib, Hydrochloride Salt **


Erlotinib, Hydrochloride Salt **  的詳細介紹
Erlotinib, Hydrochloride Salt **

產品名稱:Erlotinib, Hydrochloride Salt
產品貨號:LC  E-4007 
產品規(guī)格:10 G
Inhibitor of the epidermal growth factor receptor tyrosine kinase, which is highly expressed and occasionally mutated in various forms of cancer.  Erlotinib binds reversibly to the ATP binding site of the receptor.  Raymond, E., et al.  "Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy."  Drugs 60 Suppl 1:  15-23, discussion 41-42 (2000).
Erlotinib is an inhibitor of human EGFR tyrosine kinase (IC50 = 2 nM) and decreases EGFR autophosphorylation in tumor cells (IC50 = 20 nM).  Moyer, J.D., et al.  "Induction of Apoptosis and Cell Cycle Arrest by erlotinib, an Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase."  Cancer Res. 57:  4838-4848 (1997).
Erlotinib has been shown to be a potent inhibitor of JAK2-V617F, a mutant of tyrosine kinase JAK2 found in a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia and most patients with polycythemia vera (PV).  The study indicates that erlotinib may be used to treat JAK2-V617F-positive PV and other myeloproliferative disorders.  Li, Z., et al. "Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth."  J. Biol. Chem. 282:  3428-3432 (2007).
Found to be a potent inhibitor of EGFR kinase (Ki = 0.7 nM), but much weaker for ErbB-2 kinase (Ki = 1 µM) and ErbB-4 kinase (Ki = 1.5 µM).  Wood, E.R., et al.  "A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib), Relationships among Protein Conformation, Inhibitor Off-Rate, and Receptor Activity in Tumor Cells."  Cancer Res. 64:  6652-6659 (2004).
Erlotinib is the active ingredient in the drug sold under the trade name Tarceva®.  This drug has been approved in at least one country for use in patients with pancreatic cancer, non-small cell lung cancer and several other types of cancer.  NOTE:  THE ERLOTINIB, HYDROCHLORIDE SALT RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT TARCEVA®, AND IS NOT FOR HUMAN USE.
Storage:  Store at or below -20 ºC.  Solubility:  Soluble in DMSO at 18 mg/mL with warming; very poorly soluble in ethanol; very poorly soluble in water; maximum solubility in plain water is estimated to be about 5-20 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility.  Disposal:  A

產品留言
標題
聯(lián)系人
聯(lián)系電話
內容
驗證碼
點擊換一張
注:1.可以使用快捷鍵Alt+S或Ctrl+Enter發(fā)送信息!
2.如有必要,請您留下您的詳細聯(lián)系方式!
使用指南 付款方式 客戶關懷 **與保密 法律幫助 服務條款 監(jiān)察中心信箱
分享到:

滬公網(wǎng)安備 31011002002623號